Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DRIXORAL PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DRIXORAL PLUS.
ACUVUE THERAVISION WITH KETOTIFEN vs DRIXORAL PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
DRIXORAL PLUS contains dexbrompheniramine, an antihistamine that competes with histamine for H1-receptor sites, suppressing histamine-induced symptoms; and pseudoephedrine, a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1 tablet orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Pseudoephedrine: ~9-16 hours (pH-dependent, longer in alkaline urine). Dexbrompheniramine: ~20-25 hours. Clinical context: multiple dosing accumulates.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Renal: 50-70% unchanged for pseudoephedrine; hepatic metabolism for dexbrompheniramine with renal excretion of metabolites.
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine/Decongestant